Insulin Resistance in Women: What the Symptoms Look Like Before the Glucose Rises

She is 47, a patient who has come in for a general physical. She mentions, almost in passing, that she has been gaining weight for the past two years without changing how she eats or how much she exercises. She is tired after lunch. Not drowsy in the way of poor sleep, but a specific, concrete fatigue that arrives about forty minutes after a meal and lifts again by mid-afternoon. Her periods, which were regular until her mid-thirties, have been arriving every 38 to 45 days for the past four years. She assumed the cycle irregularity was early perimenopause. Her previous physician said the same.

Her lab results come back from the routine panel. Fasting glucose: 94 mg/dL. Normal. HbA1c: 5.4 percent. Normal. Lipids mostly within range. Thyroid normal. She is told her labs look good and to keep up whatever she is doing.

Her fasting insulin was never measured. It was 18 µIU/mL. A level that high, in combination with a fasting glucose of 94, produces a HOMA-IR of approximately 4.2, placing her firmly in the insulin-resistant range. She has been metabolically abnormal for years. Her glucose tests will not show it for another five to ten years, if ever. By the time her fasting glucose crosses 100, the vascular and cardiovascular damage already accumulating will have been progressing for a decade.

This is not a rare story. It is, for women, the common one.

What Insulin Resistance Actually Is

To understand why the glucose tests miss it, you need to understand what insulin resistance is at the cellular level.

When you eat carbohydrates, glucose enters the bloodstream. The pancreas detects the rise and releases insulin. Insulin travels to skeletal muscle, adipose tissue, and the liver, where it binds to its receptor on the cell surface. That binding triggers a phosphorylation cascade inside the cell, ultimately causing a protein called GLUT4 to translocate from vesicles inside the cell to the cell membrane. GLUT4 is the glucose transporter. Once it reaches the membrane, glucose can enter the cell and be used for energy or stored as glycogen. Blood glucose falls. The system returns to baseline.

In insulin resistance, the problem is in the signaling cascade. Insulin binds its receptor normally, but somewhere downstream in the phosphorylation chain, the signal is impaired. GLUT4 translocation is reduced. Glucose enters cells more slowly. The pancreas senses that glucose is not clearing as expected, and it does what it is designed to do: it produces more insulin. If the beta cells are healthy and the resistance is moderate, this compensatory hyperinsulinemia is sufficient to maintain normal blood glucose. The glucose reading stays at 94. The HbA1c stays at 5.4.

But the insulin required to achieve that result is now pathologically elevated. Fasting insulin that should be between 2 and 6 µIU/mL is running at 18 or 22. This hyperinsulinemia is not a benign compensatory state. It is the active pathological condition driving most of the downstream cardiovascular and metabolic damage. It stimulates androgen production. It promotes fat storage. It activates the renin-angiotensin-aldosterone system. It drives endothelial dysfunction. It acts as a growth factor in tissues where it has no business acting as one.

The glucose tests detect diabetes when the pancreatic beta cells can no longer compensate and glucose finally rises. They detect nothing during the preceding decade of hyperinsulinemic insulin resistance, which is exactly the period when effective intervention would matter most.

PCOS: Insulin Resistance Starting in the Twenties

Polycystic ovary syndrome affects 8 to 13 percent of women of reproductive age, making it one of the most common endocrine disorders in women. Insulin resistance is present in 70 to 80 percent of women with PCOS, regardless of body weight. Lean women with PCOS have insulin resistance at rates that make clear this is not a consequence of obesity but a central feature of the condition itself.

The mechanism matters here. Elevated insulin acts directly on the ovarian theca cells through a pathway that is independent of luteinizing hormone. Theca cells produce androgens, primarily testosterone and androstenedione. When insulin is high, it drives theca cell androgen production upward. Elevated androgens disrupt follicular development, producing the oligo- or anovulation that defines PCOS clinically, along with the acne, hirsutism, and male-pattern hair thinning that many women with PCOS experience.

The causal direction matters: the woman with PCOS does not have irregular periods because of some separate ovarian dysfunction that happens to coexist with insulin resistance. In most cases, she has irregular periods because she is insulin resistant, and the hyperinsulinemia is driving the androgen excess that disrupts her cycle. Treating the insulin resistance, whether with lifestyle modification or metformin, often improves menstrual regularity because it addresses the upstream driver.

The cardiovascular consequence of PCOS-related insulin resistance is not a midlife phenomenon. It begins in the second decade of life. A 19-year-old with PCOS and fasting insulin of 20 µIU/mL has been accumulating endothelial dysfunction, atherogenic lipid changes, and inflammatory burden for years before she sees a gynecologist about her irregular periods. Studies tracking carotid intima-media thickness, a structural marker of early atherosclerosis, show measurably thicker intima-media in young women with PCOS compared to controls matched for age, BMI, and blood pressure.

The woman who is told in her twenties that her PCOS is a fertility issue is receiving an incomplete clinical picture. It is, simultaneously, a long-term cardiovascular risk classification that should shape her metabolic monitoring for the rest of her life.

Acanthosis Nigricans: The Skin Signal That Gets Dismissed

Acanthosis nigricans is a dermatological finding that most women first notice in a dressing room mirror and most physicians first mention only after it has been present for years. It presents as a velvety, hyperpigmented thickening of skin in the flexural areas: the back of the neck, the axillae, the groin, and, in women, commonly under the breasts. The texture is not rough or scaly. It has a soft, almost velvety quality, and the color ranges from tan to dark brown depending on baseline skin tone.

The mechanism is not primarily melanin deposition. Elevated insulin acts through the insulin-like growth factor 1 receptor on keratinocytes and dermal fibroblasts, stimulating these cells to proliferate at pathologically elevated insulin concentrations. The resulting cellular proliferation produces the characteristic thickening and the appearance of darker skin due to increased cell density. It is a direct skin-level consequence of hyperinsulinemia, not a pigmentation disorder.

In women, the distribution under the breasts is particularly common and particularly frequently missed. Routine clinical visits do not include examination of the inframammary fold, and women who notice the change there often attribute it to friction or heat irritation. It gets treated with antifungals or topical creams. Neither addresses the underlying metabolic cause. Treating the skin finding without addressing the hyperinsulinemia produces no meaningful or lasting improvement in the skin, and delays appropriate metabolic assessment by months or years.

The critical clinical point: acanthosis nigricans indicates pathological hyperinsulinemia regardless of body weight. A woman with a BMI of 23 who has visible acanthosis nigricans at her neckline is displaying a metabolic signal. Her normal weight does not reduce the significance of the finding. If anything, the absence of obesity makes it more important to investigate rather than less, because it narrows the differential to hyperinsulinemia as an explanation.

Menstrual Irregularity as a Metabolic Biomarker

The menstrual cycle is a sensitive physiological signal. It requires coordinated function of the hypothalamic-pituitary-ovarian axis, adequate estrogen and progesterone signaling, and sufficient metabolic substrate. It is disrupted by undernutrition, extreme exercise, thyroid dysfunction, hyperprolactinemia, and insulin resistance. This last cause is underweighted in clinical practice relative to its frequency.

Insulin resistance disrupts the HPO axis through multiple pathways. Elevated insulin increases LH pulse frequency and amplitude, favoring androgen production over follicular maturation. Hyperinsulinemia also reduces hepatic production of sex hormone-binding globulin, increasing free testosterone levels even without a change in total testosterone production. Elevated free androgens disrupt the selection and maturation of the dominant follicle, producing oligomenorrhea (cycles longer than 35 days) or anovulatory cycles in which no ovulation occurs at all.

A woman who had regular 28- to 30-day cycles through her twenties and then develops progressively irregular cycles extending to 35 or 40 days in her early thirties, without another explanation, should have her fasting insulin measured. If thyroid function, prolactin, and pregnancy have been excluded, and if she does not yet meet full diagnostic criteria for PCOS but has irregular cycles with any evidence of androgen excess such as new-onset acne or facial hair, insulin resistance is a likely contributor.

The clinical failure mode here is attributing any irregular cycle in a woman over 35 to early perimenopause. Perimenopause is a real and common cause of menstrual irregularity, but it typically begins in the mid-to-late forties rather than the mid-thirties. Accepting perimenopause as the complete explanation for irregular cycles in a 34-year-old forecloses a metabolic diagnosis that would change her long-term management. Fasting insulin is an inexpensive, widely available test that belongs in this differential evaluation.

The Menopause Transition and the Metabolic Pivot

Estrogen is a metabolic hormone, not only a reproductive one. Its effects on insulin sensitivity are direct and substantial. Estrogen promotes GLUT4 expression in skeletal muscle and adipose tissue, increasing the capacity for insulin-stimulated glucose uptake. It reduces hepatic glucose production. It suppresses accumulation of visceral fat and favors subcutaneous fat distribution. It maintains endothelial function through effects on nitric oxide bioavailability and inflammatory signaling in adipose and vascular tissue.

When estrogen falls at menopause, these metabolic effects are withdrawn. The same physiology that maintained insulin sensitivity for decades is removed over a period of months to years. What replaces it is a hormonal environment that is less insulin-sensitive, more prone to visceral fat accumulation, and more inflammatory. The body that was in metabolic equilibrium at 40 develops insulin resistance at 52 not because of behavioral change but because the hormonal metabolic substrate has changed.

The clinical evidence for this is not speculative. The SWAN study, a large prospective cohort that followed women through the menopause transition over multiple years, documented increases in fasting insulin, HOMA-IR, waist circumference, and visceral fat volume, alongside decreases in HDL, across women crossing the menopausal transition. These changes tracked with menopausal status rather than with age or body weight alone. Women who went through menopause earlier showed the changes earlier. Women who had surgical menopause showed them more abruptly.

The fat that accumulates in this transition is not distributed the way women recognize from earlier in life. Subcutaneous fat, which is metabolically protective and relatively anti-inflammatory, is partly replaced by visceral fat in the abdominal cavity and ectopic fat deposits in the liver and skeletal muscle. Visceral fat is metabolically active in a harmful direction: it secretes pro-inflammatory cytokines including IL-6, TNF-alpha, and resistin, each of which independently worsens insulin signaling in peripheral tissues and in the liver.

The woman who gains 12 pounds during perimenopause without changing her diet or exercise is not failing to manage herself. She is experiencing a physiological reconfiguration of her metabolic set point. The same caloric intake that maintained stable weight at 42 produces gradual weight gain at 51 because the hormonal conditions governing fuel partitioning have shifted. Telling such a woman to simply eat less and exercise more, without acknowledging this physiological context, is both incomplete and demoralizing in ways that may deter appropriate follow-up care.

Asian Women and the BMI Blind Spot

Body mass index was derived from data on white European populations and applies imprecisely to other groups. In East Asian and South Asian women, metabolic risk, including insulin resistance, type 2 diabetes, and cardiovascular disease, occurs at substantially lower BMI thresholds than conventional definitions of overweight and obesity.

The American Heart Association and the World Health Organization both recognize modified BMI thresholds for Asian populations. Overweight in Asian populations is recognized at 23 kg/m², and obesity at 27.5 kg/m². An East Asian woman with a BMI of 24, classified as normal weight by conventional criteria, may already be in the metabolically concerning range by appropriate population-specific standards.

The underlying reason is body composition. At any given BMI, Asian women tend to carry a higher percentage of body fat and, critically, a higher proportion of visceral fat relative to total adiposity. The visceral fat proportion drives metabolic risk. A woman with BMI 22 and significant visceral adiposity has more metabolic risk than a woman with BMI 27 whose fat distribution is predominantly subcutaneous. BMI cannot distinguish between these.

Waist circumference is a better approximation of visceral adiposity than BMI, though it too is imperfect. Clinically meaningful thresholds are above 80 cm for non-Asian women and above 75 cm for Asian women. A woman near or above these thresholds who also has a family history of type 2 diabetes, irregular menstrual cycles, or a parent who developed diabetes before age 60 should have fasting insulin assessed regardless of BMI.

The practical risk is this: Asian women with significant insulin resistance are routinely told their BMI is normal and that metabolic workup is therefore not indicated. This is a systematic error with measurable consequences. Type 2 diabetes disproportionately affects South Asian populations at younger ages and lower body weights than white European populations, and the same underlying metabolic trajectory is driving both the weight distribution differences and the diabetes risk. Screening based on BMI alone misses a large fraction of the at-risk population.

What Fasting Glucose and HbA1c Actually Miss

The reassurance that “your glucose is normal” is given millions of times each year to women who are, at that moment, in the middle of a prolonged insulin-resistant state. This is worth being explicit about, because the phrase functions as a clean bill of metabolic health when it is not.

The pancreas compensates for insulin resistance by producing more insulin. During the compensatory phase, which can persist for 10 to 15 years or longer, the beta cells are working harder than normal but they are working. Blood glucose is cleared, because the higher insulin output is sufficient to overcome the impaired downstream signaling. A fasting glucose of 92 mg/dL is completely normal. A two-hour post-load glucose of 130 mg/dL is below the 140 mg/dL threshold for impaired glucose tolerance. An HbA1c of 5.4 percent is well within the normal range.

None of these tests measure insulin. All of them will be normal as long as the beta cells can compensate. The only test that identifies the problem during this phase is a direct measurement of fasting insulin, ideally alongside a fasting glucose to calculate HOMA-IR.

HOMA-IR is calculated as fasting insulin in µIU/mL multiplied by fasting glucose in mg/dL, divided by 405 using US units. A HOMA-IR above 1.7 to 2.0 suggests insulin resistance in most clinical references, though threshold definitions vary. Fasting insulin above 7 µIU/mL is an earlier and more sensitive signal of the resistant state, and some clinicians use a lower threshold of 5 µIU/mL for women with PCOS symptoms.

The patient at the beginning of this article had a fasting insulin of 18 µIU/mL, producing a HOMA-IR of approximately 4.2, clearly in the resistant range, with entirely normal glucose-based results. She had both tests available on the same blood draw. One was ordered. One was not.

The glucose tests detect diabetes when the beta cells fail. They detect nothing useful during the decade-plus of hyperinsulinemic compensation that precedes that failure. The appropriate clinical response to a woman with symptoms consistent with insulin resistance is not to order glucose-based tests and declare the result normal. It is to measure the hormone that is actually elevated.

The Cardiovascular Consequence

The reason insulin resistance in women deserves a cardiovascular frame is that the damage begins at the vessel wall years before any glucose elevation appears.

Hyperinsulinemia activates the renin-angiotensin-aldosterone system. Elevated insulin increases sodium retention by the kidney and promotes vascular smooth muscle proliferation, raising blood pressure through mechanisms that operate independently of other risk factors. The blood pressure elevation that many women develop in their late forties is not only an age-related phenomenon. In women with underlying insulin resistance, hyperinsulinemia is a contributing driver.

Elevated insulin drives hepatic production of VLDL particles, increasing circulating triglycerides. Simultaneously, insulin resistance impairs the activity of lipoprotein lipase, reducing VLDL clearance and further elevating triglycerides. High triglycerides promote exchange of triglycerides for cholesterol esters in HDL particles through cholesteryl ester transfer protein, reducing HDL size and accelerating its clearance from the circulation. The resulting pattern, elevated triglycerides and low HDL, alongside a shift of LDL toward smaller denser particles, is the atherogenic dyslipidemia that characterizes insulin-resistant states. It is a more atherogenic lipid profile than an isolated LDL elevation at comparable numbers.

Insulin resistance also impairs endothelial function. Nitric oxide, produced by endothelial cells, maintains vascular tone, inhibits platelet aggregation, and reduces inflammatory cell adhesion to the vessel wall. Insulin resistance reduces nitric oxide bioavailability through increased reactive oxygen species and elevated asymmetric dimethylarginine, a competitive inhibitor of nitric oxide synthase. Early endothelial dysfunction can be detected by flow-mediated dilation testing years before any structural plaque forms.

The visceral fat accumulating in insulin-resistant women is itself an active endocrine organ. Visceral adipocytes secrete IL-6, TNF-alpha, and CRP precursors into the portal circulation, directly reaching the liver and cardiovascular system. These inflammatory signals worsen insulin signaling, increase hepatic glucose production, promote atherogenesis, and destabilize existing atherosclerotic plaques. The inflammatory load from visceral fat is not peripheral: it arrives at the liver and cardiovascular system concentrated through the portal route.

In women, all of this converges in a narrow window. Cardiovascular risk accelerates in the decade after menopause. Hypertension rates rise. Arterial stiffness, measured by pulse wave velocity, increases more rapidly in postmenopausal women than in age-matched men. The hormonal cardiac protection that estrogen provided through its effects on lipids, endothelial function, and inflammation is withdrawn precisely when insulin resistance may be worsening and visceral fat is accumulating. These processes reinforce each other.

A woman with PCOS who enters perimenopause at 48 and has been insulin resistant since her twenties has accumulated three decades of cardiovascular exposure before her physician initiates a cardiovascular prevention conversation. Standard cardiovascular screening timelines were not designed for this trajectory.

What Reduces Insulin Resistance in Women

Resistance training deserves priority here, because skeletal muscle is the primary site of insulin-stimulated glucose disposal. Approximately 70 to 80 percent of glucose that enters cells after a meal does so in skeletal muscle. Increasing muscle mass increases the absolute capacity for glucose disposal. Improving the insulin sensitivity of existing muscle, which resistance training accomplishes through GLUT4 upregulation and improved mitochondrial function, multiplies the effect further.

Studies in women with PCOS and in postmenopausal women both show that resistance training improves HOMA-IR independent of body weight change. This is an important distinction: the metabolic improvement from resistance training is not entirely mediated by weight loss. A woman who gains 2 kilograms of muscle while losing 2 kilograms of fat may show no change on the scale but measurable improvement in insulin sensitivity. Body weight alone is a poor proxy for the metabolic effect of resistance training.

Dietary glycemic quality matters independently of total caloric intake. Reducing refined carbohydrate load in favor of fiber-rich whole foods with lower glycemic index reduces the frequency and magnitude of postprandial insulin excursions. Over time, reducing the cumulative insulin burden appears to improve insulin sensitivity in peripheral tissues. The effect is not primarily driven by caloric restriction, though caloric moderation contributes where excess adiposity is a factor. The quality of carbohydrate, not simply its quantity, is the more relevant variable for women managing insulin resistance through diet.

Sleep is underestimated as a metabolic intervention. Controlled data show that restricting sleep from 8 hours to 6 hours per night for one week produces measurable deterioration in insulin sensitivity. Women averaging 6 hours of sleep show higher HOMA-IR than those averaging 8, independent of adiposity. In perimenopausal women, where vasomotor symptoms already threaten sleep continuity throughout the night, the metabolic consequences of disrupted sleep add another reinforcing layer to the insulin resistance problem. Addressing sleep is a metabolic intervention, not merely a quality-of-life one.

Where significant excess weight is present, a 10 percent reduction in body weight produces clinically meaningful improvement in HOMA-IR. The improvement is non-linear: early weight loss produces disproportionately large metabolic gains relative to later loss. The first 5 to 10 percent of body weight lost often yields the greatest per-kilogram improvement in insulin sensitivity.

Metformin is used in specific clinical contexts, most notably PCOS with documented insulin resistance and in high-risk prediabetes. It reduces hepatic glucose production and modestly improves peripheral insulin sensitivity. Its use requires physician evaluation of indications, contraindications, and appropriate monitoring.

What to Ask Your Doctor This Week

The gap between what routine lab panels measure and what would actually detect insulin resistance is not a technical barrier. Fasting insulin is a standard laboratory test processed by every major commercial lab. It requires a fasting blood draw, the same one already taken for a fasting glucose. Adding it to an existing order takes less than thirty seconds.

If you have irregular menstrual cycles, unexplained weight gain, post-meal fatigue, visible acanthosis nigricans at your neck or axillae, or a personal or family history of PCOS or type 2 diabetes, ask your physician to add fasting insulin to your next fasting metabolic panel. If fasting insulin returns above 7 µIU/mL, ask your physician to calculate HOMA-IR and discuss what it means for your cardiovascular risk tier, not only your diabetes risk. Insulin resistance is a cardiovascular risk factor. It belongs in the cardiovascular prevention conversation.

If you carry a PCOS diagnosis and have been managing it primarily through cycle regulation or fertility treatment, ask whether your insulin resistance has been formally quantified recently and whether it is being addressed as a long-term cardiovascular concern. PCOS management that addresses only reproductive manifestations, without treating the metabolic substrate driving them, leaves the most consequential aspect of the condition unmanaged.

If you are in perimenopause and have developed unexplained weight gain despite stable behavior, a response of “eat less, move more” is not a complete clinical answer. Ask specifically: has insulin resistance been assessed through fasting insulin, not only through fasting glucose? What does the perimenopause transition mean for my long-term metabolic and cardiovascular trajectory? What changes in monitoring are appropriate now?

The patient at the start of this article was not failed by abnormal results that went unnoticed. She was failed by a normal result on the wrong test, and by the absence of the right one. That is a correctable problem. The correction begins with knowing what question to ask.

The Women’s Signal Check is fifteen questions mapping the female cardiovascular risk pattern, including reproductive history, microvascular signals, and the factors standard risk calculators do not capture. It produces a specific starting point for your next clinical conversation.